Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.40 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.40 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.40 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.36 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.35 |
| ▸ | PYGB | P11216 | 3/20 | 0.34 |
| ▸ | PYGL | P06737 | 2/20 | 0.34 |
| ▸ | PYGM | P11217 | 1/20 | 0.34 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4849439 | 0.88 | SLC28A1 (0.47) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28843545 | 0.88 | SLC28A1 (0.37) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL31280115 | 0.86 | SLC28A1 (0.39) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28236932 | 0.86 | SLC28A1 (0.40) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY14 | |
| SCHEMBL17728070 | 0.85 | SLC28A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28843518 | 0.84 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL5964454 | 0.82 | SLC28A1 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL6754600 | 0.82 | SLC28A1 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL382353 | 0.82 | SLC28A1 (0.35) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL29780672 | 0.82 | P2RY14 (0.36) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103328655-A | Signal amplification | SPEEDX PTY LTD | 2013-09-25 | — | — | CN | claimed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-23 | — | — | US | disclosed |
| EP-4218748-A2 | BMP-MIMETICS | Christian-Albrechts-Universität zu Kiel (DE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023015200-A1 | AMNIOTIC FLUID STABILIZED COMPOSITIONS AND METHODS FOR IN UTERO DELIVERY OF THERAPEUTIC AGENTS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-3920976-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | Orna Therapeutics, Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| WO-2021113777-A2 | CIRCULAR RNA COMPOSITIONS AND METHODS | ORNA THERAPEUTICS, INC. (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-105814202-A | NOTCH1 specific SIRNA molecules | 佐路闻蒂斯有限公司 | 2016-07-27 | — | — | CN | disclosed |
| CN-101932609-B | Compositions and methods for modulating cell membrane resealing | RUTGERS THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-03-23 | — | — | CN | disclosed |
| CN-103269713-B | Antigen delivery platform | NOVARTIS AG (CH) | 2016-01-20 | — | — | CN | disclosed |
| CN-101557818-A | ATAP peptides, nucleic acids encoding the same, and related methods of use | UNIV NEW JERSEY MED (US) | 2009-10-14 | — | — | CN | disclosed |
| CN-100510101-C | Methods and compositions for detecting SARS virus and other infectious agents | CAPITALBIO CORP TSINGHUA UNIVE (CN) | 2009-07-08 | — | — | CN | disclosed |
| CN-100480397-C | Biochip for detecting SARS virus | CAPITALBIO CORP SINGHUA UNIVER (CN) | 2009-04-22 | — | — | CN | disclosed |
| CN-101068813-A | Determination of Nucleic Acids Using Electrocatalytic Intercalators | AGENCY SCIENCE TECH & RES (SG) | 2007-11-07 | — | — | CN | disclosed |
| CN-1906309-A | Marker Lmx1a specific for dopamine-producing neurons | EISAI CO LTD (JP) | 2007-01-31 | — | — | CN | disclosed |
| CN-1802438-A | Method and composition for detecting SARS virus | CAPITALBIO CORP (CN) | 2006-07-12 | — | — | CN | disclosed |
| CN-1802440-A | Methods and compositions for detecting SARS virus and other infectious agents | CAPITALBIO CORP (CN) | 2006-07-12 | — | — | CN | disclosed |
| EP-1261734-A1 | GENOMIC ANALYSIS OF tRNA GENE SETS | Montclair Group (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001062955-A1 | GENOMIC ANALYSIS OF tRNA GENE SETS | MONTCLAIR GROUP (US) | 2001-08-30 | — | — | WO | disclosed |
| CN-1261920-A | Enzymatic DNA molecules | SCRIPPS RESEARCH INST (US) | 2000-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240165267-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | SLC28A1 231/4885SLC28A2 204/4885SLC29A1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.